Showing results (41-50 of 142) with videos related to
Sort By:
Pageof 15
Trials|September 8, 2021
The future is now: our experience starting a remote clinical trial during the beginning of the COVID-19 pandemicHans H Liu, Michael D Ezekowitz, Michele Columbo, et al.Mammalian Genome : Official Journal of the International Mammalian Genome Society|June 1, 2013
A coding variant in SR-BI (I179N) significantly increases atherosclerosis in miceAntonino Picataggi, Geoffrey F Lim, Anthony P Kent, et al.Journal of Interventional Cardiac Electrophysiology : an International Journal of Arrhythmias and Pacing|February 2, 2015
A placebo-controlled, double-blind, randomized, multicenter study to assess the effects of dronedarone 400 mg twice daily for 12 weeks on atrial fibrillation burden in subjects with permanent pacemakersMichael D Ezekowitz, Kenneth A Ellenbogen, John P DiMarco, et al.Stroke|April 12, 2012
Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trialRobert G Hart, Hans-Christoph Diener, Sean Yang, et al.Thrombosis and Haemostasis|January 29, 2016
D-dimer and factor VIIa in atrial fibrillation - prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudyAgneta Siegbahn, Jonas Oldgren, Ulrika Andersson, et al.American Heart Journal|April 21, 2009
Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatranMichael D Ezekowitz, Stuart Connolly, Amit Parekh, et al.Journal of Neurosurgery|November 28, 2015
Decompressive hemicraniectomy: predictors of functional outcome in patients with ischemic strokeBadih Daou, Anthony P Kent, Maria Montano, et al.American Heart Journal|December 19, 2015
Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillationJulia Aulin, Agneta Siegbahn, Ziad Hijazi, et al.European Heart Journal|March 15, 2005
High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trialAnders G Olsson, Gregory G Schwartz, Michael Szarek, et al.Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology|April 26, 2008
Beneficial effects of fenofibrate on plaque thrombogenicity and plaque stability in atherosclerotic rabbitsEmmanuelle Jeanpierre, Thierry Le Tourneau, Christophe Zawadzki, et al.Pageof 15